Watch the latest episode of focusIR Fireside Chats: Why Edinburgh Investment Trust Is Backing Turnaround Stocks for 2026 Growth. View here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Regulatory News (GSK)

Share Price Information for Glaxosmithkline (GSK)

Share Price is delayed by 15 minutes
Get Live Data
1,983.00    -0.50 (-0.03%)
Bid:
1,978.50
Ask:
1,979.50
Spread: 1.00 (0.051%)
Market Cap: £79.45b
GSK Live PriceLast checked at - London Stock Exchange

Intraday Glaxosmithkline Share Chart

Director/PDMR Shareholding

5 May 2026 15:30

RNS Number : 0889D
GSK PLC
05 May 2026
 

GSK plc (the 'Company')

 

2026 Award under the Deferred Investment Award Programme

Notional Award

 

On 1 May 2026, the Company granted an award over notional Ordinary Shares to Roanne Parry, a Person Discharging Managerial Responsibilities ('PDMR'), under the GlaxoSmithKline Deferred Investment Award programme. The award has been granted upon Ms Parry joining GSK as Chief People Officer and a newly appointed Executive Committee member.

 

Under the programme, awards are made over notional Ordinary Shares with vesting over a specified period to provide long-term alignment with shareholders. Vesting is subject to the PDMR not having served the Company notice or having been terminated by the Company for cause. Dividends will accrue on the award during the vesting period. On vesting, the award will be paid in cash. The award will vest in two increments: 34.22% of the award will vest on 31 August 2028 and 65.78% of the award will vest on 31 August 2029.

 

Executive Directors are not eligible to receive awards under the programme.

 

Transaction notification

 

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Roanne Parry

b)

Position/status

Chief People Officer

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GSK plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

Ordinary shares of 31 ¼ pence each ('Ordinary Shares')

 

ISIN: GB00BN7SWP63

b)

Nature of the transaction

A restricted award of notional Ordinary Shares under the Company's Deferred Investment Award programme.

 

c)

Price(s) and volume(s)

Price(s)

Volume(s)

£19.01

35,507.628

d)

Aggregated information

 

N/A (single transaction)

 

Aggregated volume Price

e)

Date of the transaction

2026-05-01

f)

Place of the transaction

 

N/A

 

 

About GSK

GSK is a global biopharma company with a purpose to unite science, technology, and talent to get ahead of disease together. Find out more at www.gsk.com.

 

Registered in England & Wales:

No. 3888792

 

Registered Office:

79 New Oxford Street

London

WC1A 1DG

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
DSHSSAFFIEMSEFI
Date   Source Headline
7th Jun 202212:00 pmEQSHardman & Co Life Sciences Research: Long-term pharmaceutical industry cost and EBIT analysis
6th Jun 20227:00 amRNSUS FDA approval of Priorix
1st Jun 20224:55 pmRNSTotal Voting Rights
1st Jun 20221:00 pmRNSDemerger update: Publication of Documents
1st Jun 20227:00 amRNSDemerger update: Submission of Documents to FCA
31st May 20227:00 amRNSGSK to acquire Affinivax, Inc.
30th May 202210:00 amRNSFurther appointments to Designate Haleon Board
27th May 20227:00 amRNSGSK Cervarix two-dose schedule approved by NMPA
25th May 20223:41 pmPRNDirector/PDMR Shareholding
23rd May 20223:21 pmRNSDirector/PDMR Shareholding
19th May 202210:02 amRNSIain Mackay - External Appointment
16th May 20222:00 pmRNSChange of name to GSK plc
13th May 20225:13 pmRNSDirector/PDMR Shareholding
12th May 20228:58 amRNSDirector/PDMR Shareholding
11th May 20225:17 pmRNSBlock listing Interim Review
9th May 20222:53 pmRNSDirector/PDMR Shareholding
4th May 20225:49 pmRNSResult of AGM
4th May 202210:00 amRNSDirectorate Change
3rd May 20224:52 pmRNSTotal Voting Rights
27th Apr 20227:00 amRNS1st Quarter Results
26th Apr 20229:32 amRNSDirector/PDMR Shareholding
19th Apr 20227:00 amRNSDaprodustat application accepted for review by FDA
14th Apr 20222:23 pmRNSDirector/PDMR Shareholding
14th Apr 20222:15 pmRNSDirector/PDMR Shareholding
14th Apr 20221:29 pmRNSDirector/PDMR Shareholding
13th Apr 20225:11 pmRNSDirector/PDMR Shareholding
13th Apr 20229:32 amRNSDirector/PDMR Shareholding
13th Apr 20227:00 amRNSGSK agrees to acquire Sierra Oncology for $1.9bn
12th Apr 20225:10 pmRNSDirector/PDMR Shareholding
12th Apr 20224:23 pmRNSDirector/PDMR Shareholding
12th Apr 20224:00 pmRNSDirector/PDMR Shareholding
12th Apr 20223:48 pmRNSDirector/PDMR Shareholding
1st Apr 20224:03 pmRNSTotal Voting Rights
1st Apr 202211:20 amRNSGSK - segment and product sales reporting changes
28th Mar 20221:00 pmRNSPublication of 2022 AGM Notice
24th Mar 20223:22 pmRNSDirector/PDMR Shareholding
24th Mar 20222:00 pmRNSFDA update: Cabenuva oral lead-in now optional
23rd Mar 20225:03 pmRNSDirector/PDMR Shareholding
23rd Mar 20227:00 amRNSIssuance of Notes
16th Mar 20222:40 pmRNSDirector/PDMR Shareholding
15th Mar 20222:45 pmRNSDirector/PDMR Shareholding
15th Mar 202210:00 amRNSAppointments to Designate Haleon Board
11th Mar 20222:55 pmRNSDirector/PDMR Shareholding
9th Mar 20221:44 pmRNSDirector/PDMR Shareholding
8th Mar 20226:24 pmRNSGSK Annual Report 2021 on Form 20-F
4th Mar 202211:03 amRNSGSK publishes Annual Report 2021
1st Mar 20222:30 pmRNSTotal Voting Rights
1st Mar 20221:18 pmRNSDirector/PDMR Shareholding
1st Mar 20229:55 amRNSDirector/PDMR Shareholding
1st Mar 20227:00 amRNSDaprodustat application accepted for review by EMA

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.